Drug Development Progress: Positive clinical trial results for IXHL's drug candidates, like IHL-42X, generally lead to price increases, while negative results can cause price drops.

Regulatory Approvals: FDA approval or rejection of IXHL's drugs significantly impacts stock price, as approval signals market access and revenue potential.

Market Sentiment: Overall investor confidence and market trends (e.g., bullish or bearish markets) can influence the demand and price of IXHL.US shares.

Competition: The presence and success of competing therapies or drugs in the same therapeutic area as IXHL's products can affect investor perceptions and valuation.

Financial Performance: IXHL's revenue, expenses, cash flow, and profitability (if any) can influence investor confidence and stock price.

Partnerships and Collaborations: Strategic alliances or partnerships with other pharmaceutical companies can signal increased credibility and future revenue streams, potentially impacting the stock price.

News and Media Coverage: Positive or negative news reports, articles, or social media discussions about IXHL, its products, or its management can influence investor sentiment and stock price.

Economic Conditions: Broad economic factors like interest rates, inflation, and economic growth can indirectly affect investor appetite for riskier assets like biotechnology stocks.

Management Team: The experience, expertise, and perceived competence of IXHL's management team can influence investor confidence and stock valuation.

Intellectual Property: The strength and protection of IXHL's patents and intellectual property portfolio are crucial for its long-term value and can impact stock price.

Dilution: Issuing new shares (dilution) can decrease the value of existing shares, potentially lowering the stock price.